These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22726550)

  • 1. Proteasome inhibition for antibody-mediated allograft rejection.
    Sadaka B; Alloway RR; Shields AR; Schmidt NM; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):263-9. PubMed ID: 22726550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition for antibody-mediated rejection.
    Everly JJ; Walsh RC; Alloway RR; Woodle ES
    Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and investigational use of proteasome inhibitors for transplant rejection.
    Sadaka B; Alloway RR; Woodle ES
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1535-42. PubMed ID: 21916809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitor therapy for antibody-mediated rejection.
    Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
    Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of antibody-mediated rejection in transplantation.
    Sadaka B; Alloway RR; Woodle ES
    Surg Clin North Am; 2013 Dec; 93(6):1451-66. PubMed ID: 24206861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
    Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
    Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
    Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
    Liang Y; Liu H
    Curr Pharm Des; 2013; 19(18):3299-304. PubMed ID: 23151133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.
    Claes DJ; Yin H; Goebel J
    Pediatr Transplant; 2014 Jun; 18(4):E100-5. PubMed ID: 24725066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.
    Ejaz NS; Alloway RR; Halleck F; Dürr M; Budde K; Woodle ES
    Antioxid Redox Signal; 2014 Dec; 21(17):2401-18. PubMed ID: 24635140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
    Moran E; Carbone F; Augusti V; Patrone F; Ballestrero A; Nencioni A
    Semin Hematol; 2012 Jul; 49(3):270-6. PubMed ID: 22726551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
    Redfield RR; Lou Y; Rodriguez E; Rostami S; Parsons RF; Noorchashm H; Naji A; Abt PL
    Transpl Immunol; 2013 Dec; 29(1-4):11-6. PubMed ID: 24103731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation.
    Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N
    Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition reduces donor-specific antibody levels.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Brown E; Tevar A; Woodle ES
    Transplant Proc; 2009; 41(1):105-7. PubMed ID: 19249489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development and clinical application of novel proteasome inhibitors].
    Iida S
    Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.